Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Select Medical Holdings (SEM) EBITDA (2016 - 2025)

Historic EBITDA for Select Medical Holdings (SEM) over the last 17 years, with Q3 2025 value amounting to $73.0 million.

  • Select Medical Holdings' EBITDA rose 3289.5% to $73.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $293.3 million, marking a year-over-year increase of 29721.71%. This contributed to the annual value of $409.4 million for FY2024, which is 201.15% up from last year.
  • Latest data reveals that Select Medical Holdings reported EBITDA of $73.0 million as of Q3 2025, which was up 3289.5% from $86.5 million recorded in Q2 2025.
  • Select Medical Holdings' 5-year EBITDA high stood at $284.0 million for Q2 2021, and its period low was -$173.4 million during Q4 2023.
  • Its 5-year average for EBITDA is $87.7 million, with a median of $104.0 million in 2022.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 13759.43% in 2021, then crashed by 32139.18% in 2022.
  • Select Medical Holdings' EBITDA (Quarter) stood at $77.5 million in 2021, then crashed by 321.39% to -$171.7 million in 2022, then fell by 1.0% to -$173.4 million in 2023, then soared by 112.16% to $21.1 million in 2024, then soared by 245.92% to $73.0 million in 2025.
  • Its EBITDA stands at $73.0 million for Q3 2025, versus $86.5 million for Q2 2025 and $112.7 million for Q1 2025.